Advertisement

Appropriate use of cholesterol-lowering therapy

      Langsted et al. [
      • Langsted A.
      • Freiberg J.J.
      • Nordestgaard B.G.
      Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 danes without ischemic cardiovascular disease and diabetes in 2004-2014.
      ] estimated the extent of undertreatment and overtreatment with cholesterol-lowering therapy according to the European guidelines in a Danish population-based cohort without ischemic cardiovascular disease (CVD) and diabetes (n = 92.348; age 35–100 years). Eligibility and goals for guideline-recommended therapy were assessed in everyone based on 10-year risk for fatal CVD, determined from the European SCORE chart and LDL-cholesterol level. Definite undertreatment was found in 19% and definite overtreatment in 0.2% of cases, leading to the statement that ”the data clearly show that undertreatment with cholesterol-lowering therapy is a major problem, while overtreatment at most is a minor issue.”

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Langsted A.
        • Freiberg J.J.
        • Nordestgaard B.G.
        Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 danes without ischemic cardiovascular disease and diabetes in 2004-2014.
        Atherosclerosis. 2016; 257: 9-15
        • Reiner Z.
        • Catapano A.L.
        • De Backer G.
        • Graham I.
        • Taskinen M.R.
        • Wiklund O.
        • et al.
        ESC/EAS guidelines for the management of dyslipidaemias.
        Eur. Heart J. 2011; 32: 1769-1818
        • Perk J.
        • De Backer G.
        • Gohlke H.
        • Graham I.
        • Reiner Z.
        • Verschuren W.M.
        • et al.
        European guidelines on cardiovascular disease prevention in clinical practice (version 2012).
        Atherosclerosis. 2012; 223: 1-68
        • Piepoli M.F.
        • Hoes A.W.
        • Agewall S.
        • Albus C.
        • Brotons C.
        • Catapano A.L.
        • et al.
        2016 European guidelines on cardiovascular disease prevention in clinical practice.
        Atherosclerosis. 2016; 252: 207-274
        • Mortensen M.B.
        • Falk E.
        Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention.
        Eur. Heart J. Dec 2016; (online) (doi: http://dx.doi.org/10.1093/eurheartj/ehw568)
        • Mortensen M.B.
        • Nordestgaard B.G.
        • Afzal S.
        • Falk E.
        ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans.
        Eur. Heart J. Nov 2016; (online) (doi: https://doi.org/10.1093/eurheartj/ehw426)

      Linked Article